## 1 **A protein signature associated with active tuberculosis identified by plasma profiling**  2 **and network-based analysis**

3

4 Zaynab Mousavian<sup>1,2,3#</sup>, Elin Folkesson<sup>1,4,#</sup>, Gabrielle Fröberg<sup>1,5</sup>, Fariba Foroogh<sup>1,2,4</sup>, 5 Margarida Correia-Neves<sup>1,6,7</sup>, Judith Bruchfeld<sup>1,4,\$</sup>, Gunilla Källenius<sup>1,2,4,\$</sup>, Christopher 6 Sundling<sup>1,2,4,\$,  $\oint$ </sup>

- 7
- 8<sup>1</sup> Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, 9 Stockholm, Sweden
- <sup>2</sup> Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
- <sup>3</sup> School of Mathematics, Statistics, and Computer Science, College of Science, University of 12 Tehran, Tehran, Iran
- <sup>4</sup> Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
- <sup>5</sup> Department of Clinical Microbiology, Karolinska University Laboratory, Karolinska 15 University Hospital, Stockholm, Sweden
- <sup>6</sup> 16 Life and Health Sciences Research Institute, School of Medicine, University of Minho, 17 Braga, Portugal
- <sup>7</sup> 18 ICVS/3B's, PT Government Associate Laboratory, Braga, Portugal
- 19
- 20 # shared first author
- 21 \$ shared last author
- 22 § corresponding author: Christopher Sundling (christopher.sundling @ki.se).
- 23
- 24
- 25

## 26 **Abstract:**

27

28 **Objectives:** Tuberculosis (TB) is a bacterial infectious disease caused by *Mycobacterium*  29 *tuberculosis*. Annually, an estimated 10 million people are diagnosed with active TB, and 30 approximately 1.4 million dies of the disease. If left untreated, each person with active TB 31 will infect 10 to 15 new individuals every year. Therefore, interrupting disease transmission 32 by accurate early detection and diagnosis, paired with appropriate treatment is of major 33 importance. In this study, we aimed to identify biomarkers associated with the development 34 of active TB that can then be further developed for clinical testing.

35

36 **Methods:** We assessed the relative plasma concentration of 92 proteins associated with 37 inflammation in individuals with active TB  $(n=19)$ , latent TB  $(n=13)$ , or healthy controls 38 (n=10). We then constructed weighted protein co-expression networks to reveal correlations 39 between protein expression profiles in all samples. After clustering the networks into four 40 modules, we assessed their association with active TB.

41

42 **Results:** One module consisting of 16 proteins was highly associated with active TB. We 43 used multiple independent transcriptomic datasets from studies investigating respiratory 44 infections and non-TB diseases. We then identified and removed genes encoding proteins 45 within the module that were low expressed in active TB or associated with non-TB diseases, 46 resulting in a 12-protein plasma signature associated with active TB.

47

48 **Conclusion:** We identified a plasma protein signature that is highly enriched in patients with 49 active TB but not in individuals with latent TB or healthy controls and that also had minimal 50 cross-reactivity with common viral or bacterial lower respiratory tract infections.

51

52 **Keywords:** Mycobacterium Tuberculosis, Co-expression network analysis, Plasma protein 53 signature

- 54
- 55
- 56
- 57

#### 58 **Introduction:**

59

60 Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (Mtb), is an ongoing pandemic 61 responsible for approximately 10 million clinical cases and 1.4 million deaths annually, 62 making it the single deadliest infectious disease excluding the ongoing SARS-CoV2 63 pandemic. However, there are still many limitations in diagnostic methods available for 64 active TB (1, 2). Around one-fourth to one-fifth of the world's population is estimated to be 65 latently infected with Mtb (3), of which 5-10% are estimated to eventually develop active 66 disease.

67 Pulmonary TB is the most common clinical form, and it is diagnosed by detecting 68 Mtb in sputum samples by microscopy, nucleic acid amplification tests, such as PCR, and the 69 reference method mycobacterial culture. Several limitations to these methods exist; as 70 compared with culture positivity, sputum microscopy is positive only in approximately 50% 71 of cases (4) and PCR in approximately 90% of cases in respiratory samples (GeneXpert 72 RIF/TB and GeneXpert Ultra) (5, 6). Additional difficulties relate to specific patient groups, 73 such as HIV-infected patients and children, the latter commonly having low bacterial load 74 and cannot produce sputum. Mycobacterial culture can take several weeks to yield positive 75 results and requires specialized safety laboratories. In addition, it is often unavailable in 76 resource-poor settings where TB is more prevalent. In addition, the diagnosis of 77 extrapulmonary TB relies on invasive procedures to obtain samples for microbiological 78 analysis. Thus, diagnosis is frequently based on clinical and radiological findings or 79 algorithms, especially in low-resource settings. The diagnostic delays in endemic areas are 80 well-described (7) The gap between estimated and reported TB cases was more than 4 million 81 in 2020, and of those reported only 59% were microbiologically confirmed (8). No specific 82 blood test or biochemical marker has yet been introduced in the routine clinical work-up to 83 distinguish TB from other medical conditions. The need for non-sputum-based tests, both for 84 screening and diagnostic purposes is urgent and the requirements of those tests have been 85 described in detail in WHO statements for Target Product Profiles (9).

86 Over the last decades, various methods that examine the host response to Mtb 87 infection have been evaluated. Attempts at identifying TB-specific transcriptional, protein, 88 and metabolic signatures in patient blood samples were recently reviewed (10, 11). Promising 89 results have emerged for transcriptional signatures (12, 13) but no protein signature for active 90 TB has so far been validated in independent confirmatory studies. The protein signatures so 91 far identified show limited overlap and together with varying study designs and methods, this 92 makes a meta-analysis difficult (14).

93 In this study, we investigated the profile of 92 inflammatory proteins in the plasma 94 from a Swedish cohort including individuals with active TB, latent TB, and healthy controls 95 (Figure 1). Through weighted co-expression network analysis, we identified a signature that 96 was highly associated with active TB and disease severity. We refined the signature by 97 removing proteins associated with other bacterial and viral respiratory infections and 98 sarcoidosis. We then validated the signature in several independent transcriptional datasets 99 and showed it to be highly enriched in individuals with active TB.

100



- $\frac{102}{103}$
- 104

Figure 1: Flowchart of the study.

- 105 **Materials and methods:**
- 106

## 107 **Ethical considerations**

108 The study was registered and granted ethical permission from the Swedish Ethical Review 109 Board, EPN-number 2013/1347-31/2 and 2017/2262-32. All study subjects signed written 110 informed consent forms after receiving written and verbal information, in relevant cases 111 using professional interpreter services.

112

# 113 **Study participants**

114 Patients were recruited at the Karolinska University Hospital, Stockholm from May 2018 to 115 November 2019. Eligible for the study were: 1) Active TB patients within seven days of 116 treatment initiation. Active TB was defined through microbiological verification via Mtb 117 culture, or if culture negative, other microbiological positive result for Mtb (microscopy or 118 PCR) combined with clinical and radiological findings and response to anti-TB treatment 119 (active TB individuals are further described in Table S1); 2) Latent TB individuals with a 120 positive IGRA result (QuantiFERON-TB Gold In-Tube (QFT-GIT) or QuantiFERON-TB 121 Gold Plus (QFT-Plus) identified through contact investigation or screening of migrants, for 122 which active TB had been excluded. The cut-off between recent and remote TB was set to 123 two years after exposure; 3) Healthy controls with a negative IGRA-result and without 124 previously known TB-exposure, co-morbidities, or immunosuppression.

125

# 126 **Data collection**

127 Demographic, epidemiological, and clinical data for patients with active and latent TB were 128 extracted from patient charts. For all subjects this included information regarding previous 129 exposure to patients with active TB or infection, comorbidities and current medication, 130 radiological, biochemical, and microbiological test results. For the active TB cases, clinical 131 symptoms of TB disease were noted, and patients were classified according to pulmonary or 132 extrapulmonary TB. Microbiological samples for mycobacterial analysis were collected 133 independent of the study in accordance with clinical practice.

134

# 135 **Analysis of plasma proteins by proximity extension assay**

136 Venous blood samples were collected in heparin vacutainer tubes and transferred to the 137 laboratory for immediate preparation. The tubes were centrifuged at 670 *g* for 8 min after 138 which the plasma fraction was aliquoted and stored at –80 °C.

139 Patient plasma was analysed using the Olink proximity extension assay, a qPCR 140 technology that simultaneously measures combinations of cytokines in preselected panels. 141 We used the 96-protein inflammatory panel, analysing 92 protein biomarkers and 4 controls 142 (Table S2). In this automated process, specific antibodies carrying single stranded matching 143 DNA bind in pairs to each of the target proteins allowing for DNA hybridization and 144 subsequent DNA-extension. The resulting DNA, unique for each target protein, is then 145 subject to PCR amplification and finally detection. The generated results consist of 146 normalized protein expression (NPX) values that correspond to log2 transformed relative 147 protein concentrations. The assay was performed by the Translational Plasma Profile Facility 148 at SciLifeLab, Stockholm, Sweden.

149

## 150 **Protein expression data analysis**

151 Repeated samples were used between experimental batches for running bridge normalization. 152 We used *read\_NPX* and *olink\_normalization* functions from the OlinkAnalyze R package 153 (https://github.com/Olink-Proteomics/OlinkRPackage) to read the log2 NPX protein 154 expression values and perform bridge normalization between batches of our data respectively. 155 Proteins with NPX values below the limit of detection (LOD) in more than 30% of samples 156 were filtered out. To remove batch effects from the final dataset, we applied the 157 *removeBatchEffect* function from the Limma R package (15) (Figure S1). We also performed 158 differential expression analysis using the Limma R package.

159

## 160 **Weighted co-expression network analysis**

161 We used the WGCNA R package to construct a weighted protein co-expression network 162 among the proteins of our dataset. *Pearson correlation* and the *signedhybrid* network type 163 were used in the *adjacency* function of the WGCNA package. In the *signedhybrid* network 164 type, only links associated to positive correlations were retained in the network, and negative 165 correlations were discarded. Since most of the biological networks have a scale-free 166 topology, the WGCNA package in the *pickSoftThreshold* function tries to find the best value 167 of the power parameter to make a scale-free network. After network construction, the 168 network was clustered into modules containing proteins that were highly positively co-169 expressed using a hierarchical clustering algorithm as implemented in the *cutreeDynamic*  170 function of the WGCNA package with parameters deepSplit  $=$  4 and minClusterSize  $=$  5, and 171 other parameters set as default. The expression profiles of proteins in each module were 172 summarized by module eigengenes. In the *moduleEigengenes* function from the WGCNA 173 package, the first principal component of the expression data of each module is measured as a 174 module eigengene for that module. To find a module associated with TB progression, the 175 correlation between each module eigengene and the trait vector was computed to identify 176 which module that had a significant correlation with TB progression.

177

# 178 **Protein signature enrichment analysis**

To further validate the protein signature obtained from the co-expression network analysis, 180 we applied two computational methods (ssGSEA and QuSAGE) for enrichment analysis in 181 independent transcriptomic datasets. In ssGSEA, the enrichment scores of the protein 182 signature were calculated per sample based on the absolute value of proteins expression in 183 that sample to quantify how much the protein signature was overrepresented in a specific 184 sample. Moreover, to verify that the protein signature was specific to active TB and not to 185 other non-TB respiratory infections or diseases with clinical presentations similar to active

186 TB, the *qusage* function from the QuSAGE R package was applied to datasets comparing 187 active TB or non-TB disease to various control groups. The gene set differential expression 188 was calculated by combining individual probability functions obtained from individual 189 differential expression of genes in a particular comparison. A p-value, calculated by<br>190 OuSAGE, determined the statistical significance of a gene set for each given comparison. We 190 QuSAGE, determined the statistical significance of a gene set for each given comparison. We 191 also used different types of single sample gene set enrichment analysis algorithms, including 192 ssGSEA, GSVA (16) and zscore (17), all implemented in the gsva R package, to compare all 193 co-expressed modules in terms of enrichment in active TB versus latent TB and healthy 194 controls.

- 195
- 196 **Results**  197

## 198 **Clinical characteristics of the study participants**

199 The plasma of 21 individuals with active TB, 16 individuals with latent TB, and 10 healthy 200 controls were analyzed using the Olink inflammation proximity extension assay. During data 201 processing, 5 samples (2 active TB and 3 latent TB) were excluded for either failing the 202 quality control check included in the OlinkRPackage or identified as outliers by cluster 203 analysis (Figure S2). The characteristics of the remaining study participants are further 204 described in Table 1.

205 As a reflection of the low TB incidence in Sweden, most study individuals originated 206 from other countries, mainly situated in Africa, Asia and Eastern Europe. Fifteen of 19 active 207 cases had pulmonary TB including 3 with pleuritis, 6 of which were sputum smear positive. 208 Four had extrapulmonary TB cases of which two with disseminated disease. Only 1 out of the 209 19 active TB patients was not confirmed by microbiologic culture; this patient had a positive 210 PCR for *M. tuberculosis* in a lymph node aspirate and gastric lavage as well as radiologic 211 signs of active pulmonary TB and showed a clinical response to TB-treatment. The active TB 212 cases were sampled within one week of treatment initiation except for one patient that was 213 sampled at day 9. Of the 13 latent TB patients, 10 had a known recent TB exposure 1-4 214 months prior to study inclusion. All but 2 latent TB individuals completed preventive TB 215 treatment, and none progressed to active TB during a follow up period of  $> 2$  years. There 216 were few significant co-morbidities, with no patient in either group on immunosuppressive 217 treatment. All active TB patients were HIV negative. The latent TB and healthy controls were 218 not routinely tested for HIV infection.

219 From the 10 healthy controls, 1 had a QFT-Gold Plus result in the low range of the 220 borderline interval (0.35-0.99 IU/ml) but with no known exposure, potentially indicating a 221 false positive result (18, 19).



#### Table 1. Clinical characteristics of the sample cohort  $^{224}_{225}$

226<br>227

227 Patient origins; Active TB: Somalia (4) Eritrea (3), Sweden (3), Philippines (2), Peru, Bangladesh, Pakistan, 228 Mongolia, Poland, China, Afghanistan, Latent TB: Sweden (3), Romania (3), Moldavia (2), Mongolia, Ethio

228 Mongolia, Poland, China, Afghanistan. Latent TB: Sweden (3), Romania (3), Moldavia (2), Mongolia, Ethiopia, 229 Eritrea, Ghana, India.<br>230 Comorbidities; Active

230 Comorbidities; Active TB: postpartum period, hypertension (2), intestinal schistosomiasis, chronic hepatitis B, 231 acute thyroiditis. Latent TB: chronic hepatitis B, hypertension (2)

231 acute thyroiditis. Latent TB: chronic hepatitis B, hypertension (2)<br>232 C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR),

232 C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR), White blood cell count (WBC), Hemoglobin (Hb), Albumin (Alb)

233 (Hb), Albumin (Alb)<br>234 <sup>1</sup>Two patients previo 234  $\frac{1}{2}$  Two patients previously treated for ATB, 1 and 4 years before; one patient not treated 235  $\frac{2}{2}$  ATB n=19 LTBI n=9

235  $^{2}$ ATB n=19 LTBI n=9<br>236  $^{3}$ ATB n=17 LTBI n=7

 $236$  <sup>3</sup>ATB n=17 LTBI n=7<br>237 <sup>4</sup>Exposure self-reported

237  $\text{"Exposure self-reported or verified}$ <br>238 <sup>5</sup>Normal range; CRP<5, ESR <20,

238  $^{\circ}$ Normal range; CRP<5, ESR <20, WBC 4.4-10.0, Hb >120 (F),>130 (M), Alb>38<br>239  $^{\circ}$ Healthy controls: one OFT borderline (0.36/0.39), no exposure to TB

 ${}^{6}$ Healthy controls; one QFT borderline (0.36/0.39), no exposure to TB

240

# 241 **Network construction reveals one module associated with active TB**<br>242 **Following data pre-processing, including quality control, batch correction**

242 Following data pre-processing, including quality control, batch correction, and clustering the 243 relative level (NPX) of each of the 92 proteins was assessed. Proteins with more than 30% of 244 samples with NPX values below the limit of detection  $(n = 28)$  were excluded from further 245 analysis. Out of those 28 proteins, 25 had no differential expression between the groups 246 (Figure S3). A weighted protein co-expression network was constructed with the remaining 247 64 proteins to examine correlations between protein expression profiles in all included 248 samples (n = 42 individuals). We considered only the links associated with positive 249 correlations in the network reconstruction and selected power 8 to reach a scale-free topology 250 (Figure S4). After clustering the network into modules, four modules indicated by distinct 251 colours in Figure 2 were discovered (Table 2), including 34 proteins. The remaining 30 252 proteins that were not included in any of the modules, were discarded from further analysis. 253 We observed that the turquoise module out of the four modules had a significantly stronger 254 correlation with active TB (Table 2). A visual representation of the protein co-expression 255 network and the discovered protein modules were then generated using Cytoscape 3.0 (20) 256 (Figure 2).

257



258

259 Figure 2. A visual representation of the protein co-expression network and the protein modules: The protein 260 modules are surrounded by the colours turquoise, blue, brown or yellow. Nodes are coloured based on protein 261 abundance (Fold Change) in comparison of active TB vs. control, with a darker red indicating a larger fold 261 abundance (Fold Change) in comparison of active TB vs. control, with a darker red indicating a larger fold<br>262 change. Links are depicted with thickness proportional to the correlation and only links representing Pears 262 change. Links are depicted with thickness proportional to the correlation and only links representing Pearson's r  $\geq 0.6$  are shown.  $> 0.6$  are shown.

264

265



267

268 We then assessed how the markers differed between individuals with active TB, latent TB, 269 and healthy controls (Figure S5). All differentially expressed proteins ( $log2(FC) \ge 1$  and 270 FDR-corrected p-value < 0.01) between either active TB and latent TB or active TB and 271 healthy controls except FGF-21 and EN-RANGE were included in the turquoise module 272 (Figure 3). Eight of the 16 proteins in the turquoise module were highly expressed in active 273 TB patients while the remaining 8 proteins were strongly co-expressed with those highly

274 expressed proteins (Figure 2). To illustrate how the turquoise module segregated active TB 275 individuals from latent TB and healthy controls, we performed principal component analysis 276 (PCA) on the expression profile of proteins of each module and used the first and the second 277 principal components (PC1 and PC2) to show differences in protein levels (Figure S6). All 278 active TB samples except one were clearly separated from the other samples by the proteins 279 in the turquoise module, suggesting that the included proteins can potentially serve as a 280 signature to identify individuals with active TB.

281



282 Log2(Active vs. Control)<br>283 Figure 3. Differential expression analysis of all 64 proteins: Active TB vs. control (left) and active TB vs. latent<br>284 TB (right). Red points indicate the significant highly expressed protein 284 TB (right). Red points indicate the significant highly expressed proteins with  $log2(FC) > 1$  and FDR-corrected 285 P-value < 0.01 in each comparison.  $P-value < 0.01$  in each comparison.

286

## 287 **Validating the turquoise module in independent transcriptomic TB datasets**

288 There is limited overlap in markers between studies investigating protein or gene signatures 289 aiming to discriminate active TB from latent TB, healthy controls, or other diseases (Figure 290 S7). Additionally, we did not identify any available pre-processed proteomic dataset 291 including all proteins of the turquoise module that we could use for validation. For this 292 reason, we chose to instead evaluate to what extent the proteins of the different modules 293 could distinguish active TB from latent TB and healthy controls in transcriptomic datasets. 294 We applied all four modules to several independent cohorts using multiple gene set 295 enrichment analysis methods. Nine transcriptomic TB datasets were selected based on the 296 criteria of age >15, number of individuals per group >10 and no anti-TB treatment (Table 297 S3). The datasets were provided in the curatedTBData R package (21), which also included 298 the corresponding genes to all proteins included in the four modules. In total the datasets we 299 selected included >3000 individuals from four continents. Three enrichment methods (ssgsea, 300 gsva and zscore) demonstrated high enrichment of the turquoise module in active TB and low 301 enrichment in latent TB and the control group across most of the TB datasets (Figures S8- 302 S10). This was also the case for the blue module, although to a less extent compared with the 303 turquoise module. In contrast, neither the brown nor yellow modules were found highly 304 enriched in active TB using the same three methods on the same transcriptomic datasets 305 (Figures S8-S10).

306

## 307 **Identification of a new 12-protein signature for active TB diagnosis**

308 We identified the turquoise module as having the highest correlation with active TB. 309 However, two of the 16 proteins in the module, LAP TGF-beta-1 and CSF-1, had low fold 310 change values ( $log2(FC) < 0.5$ ) when comparing active TB versus both latent TB and healthy 311 controls (Figure 3), and were therefore potentially redundant.

312 To investigate if the remaining 14 proteins were specific for active TB, we performed 313 differential expression analysis using multiple transcriptomic datasets including either viral or 314 bacterial lower respiratory tract infections (LRTI), systemic inflammatory response syndrome 315 (SIRS) or sarcoidosis (Figure 4). This allowed us to identify genes encoding the signature 316 proteins that were highly and significantly expressed ( $log2(FC) > 1$  and P-value < 0.05) in 317 diseases with clinical symptoms overlapping with active TB. To this end, we used three 318 transcriptomic datasets, GSE42026 (22), GSE40012 (23) and GSE60244 (24), each 319 containing various types of lower respiratory infections. GSE42026 included (pediatric) 320 patients with severe LRTI of different etiologies; bacterial, (mostly *Streptococcus*  321 *pneumoniae*), Influenza A/H1N1/09 and Respiratory syncytial virus (RSV) infection. 322 GSE40012 included adult patients with severe community acquired pneumonia (CAP); either 323 bacterial or caused by Influenza A/H1N1, and SIRS (25), without evidence of infection. 324 Finally, GSE60244 included patients hospitalized for bacterial LRTI (*Streptococcus*  325 *pneumoniae* being most common), viral LRTI (Influenza A, B or RSV) and viral/bacterial 326 coinfection. We also conducted the same experiment using three datasets from two studies 327 containing sarcoidosis samples (26, 27). Two genes, corresponding to the proteins IL18R1 328 and CXCL10 (IP-10), stood out in these analyses (Figure 4). IL18R1 was highly expressed in 329 severe viral and bacterial LRTI and SIR, while CXCL10 was highly expressed in severe viral 330 LRTI and in one of the sarcoidosis studies. However, most of the proteins of the signature 331 were only observed to be expressed at high levels in individuals with active TB. Therefore, in 332 addition to LAP TGF-beta-1 and CSF-1 that were expressed only at very low levels, we also 333 removed IL18R1 and CXCL10 from the signature, leading to a 12-marker plasma signature 334 associated with active TB and with low cross-reactivity to other bacterial/viral lower 335 respiratory infections and sarcoidosis. The final signature consisted of the proteins IFN-336 gamma, IL6, CDCP1, CXCL9, MMP-1, MCP-3, CCL19, CD40, VEGFA, IL7, IL-12B and 337 PDL-1.



338<br>339

#### Fold change (active TB vs. controls)

339 Figure 4. The expression of proteins of the turquoise module in our Swedish cohort compared to other 340 viral/bacterial infections, SIRS and sarcoidosis from different datasets. The fold-changes of proteins of the turquoise module in our cohort (active TB vs. controls: x-axis) compared to their fold-changes in other non-341 turquoise module in our cohort (active TB vs. controls; x-axis) compared to their fold-changes in other non-TB<br>342 diseases (non-TB diseases vs. controls; y-axis). Red points indicate proteins of the turquoise module, 342 diseases (non-TB diseases vs. controls; y-axis). Red points indicate proteins of the turquoise module, which genes encoding them are significantly highly expressed in either other infections or other diseases (log2(FC 343 genes encoding them are significantly highly expressed in either other infections or other diseases (log2(FC) > 1<br>344 and P-value < 0.05). Row 1). Pediatric patients with severe respiratory tract infection: Bacterial: and P-value  $\lt$  0.05). Row 1). Pediatric patients with severe respiratory tract infection: Bacterial: (n=18,

345 *Streptococcus pneumonia* (12), *Streptococcus pyogenes* (4) *Staphylococcus aureus* (2) including 5 with viral co-346 infection (non-Influenza A H1N1/RSV); Influenza A/H1N1 (n=19), RSV (n=22) HC (n=33). Row 2) Adult patients with severe CAP or SIRS requiring ICU-care: Bacterial: (n=16, mixed etiology) Influenza 347 patients with severe CAP or SIRS requiring ICU-care: Bacterial:  $(n=16)$ , mixed etiology) Influenza 348 A/H1N1 $(n=8)$ , SIRS without infection  $(n=12)$ , HC  $(n=18)$ . Row 3) Adult patients hospitalized for LRTI:  $348$  A/H1N1(n=8), SIRS without infection (n=12), HC (n=18). Row 3) Adult patients hospitalized for LRTI:<br> $349$  Bacterial (n=22; S. pneumoniae (13), Moraxella catarrhalis (4), S. aureus (2), mixed bacterial (3); viral (n= 349 Bacterial (n=22; *S. pneumoniae* (13), *Moraxella catarrhalis* (4), *S. aureus* (2), mixed bacterial (3); viral (n=71, 350 Influenza A (32), RSV (17), Influenza B (9), HMPV (7); mixed bacterial/viral (n=25) HC (n=40). Row 4) pulmonary sarcoidosis vs controls. RSV = respiratory syncytial virus; CAP = Community acquired pneumonia; 351 pulmonary sarcoidosis vs controls. RSV = respiratory syncytial virus; CAP = Community acquired pneumonia; 352 ICU = Intensive Care Unit; SIRS = systemic inflammatory response syndrome; LRTI = Lower respiratory tract 352 ICU = Intensive Care Unit; SIRS = systemic inflammatory response syndrome; LRTI = Lower respiratory tract  $infection$ ;  $HMPV = human metapneumovirus$ 

354

#### 355 **Validating the 12-marker signature in TB and non-TB proteomic and transcriptomic**  356 **datasets**

357 To assess the significance of the 12-marker signature in independent TB cohorts, we 358 performed ssGSEA on transcriptomic TB datasets from the curatedTBData R package (Table 359 S3). We observed significantly ( $p < 0.05$ ) higher enrichment scores in the active TB group, S3). We observed significantly ( $p < 0.05$ ) higher enrichment scores in the active TB group, 360 compared with either latent TB or controls in all the transcriptomic TB datasets except one 361 (GSE19444) (Figure 5A). We then used QuSAGE to compare the enrichment of the 12 marker signature in TB infections with both other bacterial/viral infections and other 363 pulmonary diseases (Figure 5B). Three different comparisons were done using the 364 GSE42026, GSE40012 and GSE60244 datasets to assess the signature in respiratory 365 infections versus healthy controls, and in sarcoidosis disease versus healthy controls using 366 three transcriptomic datasets (GSE83456, GSE42826 and GSE42830) (Figure 5B). We 367 observed that the 12-marker signature was significantly overrepresented (FDR corrected P-368 value < 0.05) in all comparisons between active TB and latent TB or healthy controls but was 369 not significantly enriched in those gene sets comparing other LRTIs vs. healthy controls.<br>370 However, in two of the three sarcoidosis datasets the signature was also enriched, indicating 370 However, in two of the three sarcoidosis datasets the signature was also enriched, indicating 371 that the signature might not, on its own, be able to distinguish active TB from sarcoidosis 372 without also weighing clinical data.

373 We then compared the 12-marker signature with the other published gene signatures 374 from the TBSignatureProfiler R package (28) and published protein signatures to investigate 375 overlap between protein and transcriptional signatures with the proteins of our signature 376 (Figure 5C). VEGFA, IL6, and IFN-gamma were identified in at least two other proteomic 377 studies (29-33), while CD274 (also called PD-L1) was observed in several published 378 transcriptional signatures. IP-10 (also called CXCL10), which was removed due to its high expression in severe viral LRT and sarcoidosis appears in several proteomic studies (30-33). expression in severe viral LRT and sarcoidosis appears in several proteomic studies (30-33). 380 The other markers were less common or identified in the current study. Although these 381 proteins have not been included in protein signatures before, they have been associated with 382 TB (34-37) and could potentially be generated via similar signaling pathways in response to 383 mycobacterial infection, such as has been indicated for signal transducer and activator of 384 transcription 1 (STAT1) in TB (38). To assess if this was the case, we used the StrongestPath 385 application (39) in Cytoscape to evaluate how the proteins were connected to different STAT 386 transcription factors based on data from the KEGG database (Figure S11). We observed that 387 several of the proteins were directly associated with STAT1, consistent with previous 388 literature (38) to a lesser extent with STAT3 and STAT4, and indirectly with STAT2 and 389 STAT5A.



- 391<br>392
- 392 Figure 5. Validation and overlap of the 12-marker protein signature.<br>393 A) ssGSEA indicating enrichment score for the 12-marker signatu

393 A) ssGSEA indicating enrichment score for the 12-marker signature in different transcriptomic datasets. Blue 394 indicates individuals with active TB, orange indicates latent TB and grey indicates healthy controls. The p<br>395 values show the statistical significance for the enrichment score difference between either active TB and 395 values show the statistical significance for the enrichment score difference between either active TB and Latent 396 TB or Active TB and healthy controls using the wilcox test. B) OuSAGE analysis with -log(FDR) indicat 396 TB or Active TB and healthy controls using the wilcox.test. B) QuSAGE analysis with -log(FDR) indicating 397 capacity of the 12-marker signature in separating active TB from healthy controls (open boxes), active TB fro 397 capacity of the 12-marker signature in separating active TB from healthy controls (open boxes), active TB from<br>398 latent TB (open circles), non-infectious inflammatory disease from healthy controls (+) and other LRTIs 398 latent TB (open circles), non-infectious inflammatory disease from healthy controls (+) and other LRTIs or <br>399 SIRS from healthy controls (x). The red line indicates FDR<0.05. C) Overlap between individual proteins in  $399$  SIRS from healthy controls ( $\times$ ). The red line indicates FDR<0.05. C) Overlap between individual proteins in the 400 12-marker signature with other proteomic signatures (left) and transcriptomic signatures (right) 400 12-marker signature with other proteomic signatures (left) and transcriptomic signatures (right) from the 401 TBSignatureProfiler R package identifying active TB. TBSignatureProfiler R package identifying active TB.

#### 404 **Association between the 12-marker signature and disease severity**

405 Principal component analysis of the 12-marker signature (Figure 6A) showed that, similar to 406 the turquoise module (Figure S6), active TB was primarily separated from latent TB and 407 healthy controls by principal component 1 (PC1). We therefore hypothesized that PC1 could 408 represent a proxy for the magnitude of the inflammatory response and disease severity. To 409 evaluate if this was the case, we stratified the individuals with active TB based on their PC1 410 values and a set of clinical features (Figure 6B). The heatmap shows that samples with a 411 smaller PC1 value, located towards the left side of heatmap, were associated with several 412 biochemical markers indicating more extensive inflammation, such as lower hemoglobin 413 (Hb) and albumin (Alb), and higher erythrocyte sedimentation rate (ESR) and C-reactive 414 protein (CRP). The presence of any systemic symptoms (fever, night sweats and weight loss) 415 and smear positivity were also associated with a lower PC1 value. We next performed a 416 regression analysis to see if individual or combinations of the clinical variables could explain 417 the PC1 values. A standard least squares model including ESR (estimate: –0.03, 95% CI: – 418 0.016 -  $-0.044$ , p = 0.0008) and Alb (estimate: 0.21, 95% CI: 0.08-0.34, p = 0.006) were 419 highly associated with PC1 ( $r^2 = 0.74$ , p < 0.0001), clearly associating the signature with 420 clinical presentation (40).

421 The three active TB cases with the weakest PC1 signal had few symptoms and limited 422 disease activity and inflammation (Figure 6A). One patient had a culture-confirmed lymph 423 node TB. Another patient had a PCR positive but culture-negative lymph node and 424 pulmonary TB. The active TB case with the lowest inflammatory signal was found through 425 contact investigation very early in active disease progression with cough as the only symptom 426 but with no inflammation in laboratory tests. This suggests that the signature has the potential 427 to identify active TB very early on in the progression from latent TB.

428 Although the signature was not optimized for the detection of latent TB, the visually 429 apparent separation of latent TB from healthy controls (Figure 6A) could possibly indicate a 430 TB-specific immune response detectable in the plasma of these individuals. Two of the three 431 latent TB cases clustering with the healthy controls had no recent exposure to TB and were 432 clinically classified as remotely acquired infections (i.e., no known exposure to a TB case for  $433 > 2$  years). In summary, these data suggest that the signature could be helpful in identifying 434 TB disease progression or cure.



435

 $\overline{436}$  Figure 6. Association between the first principal component (PC1) and clinical characteristics of active TB. A) <br>437 PC1 and PC2 indicate variation in concentrations of the 12-marker signature for individuals w 437 PC1 and PC2 indicate variation in concentrations of the 12-marker signature for individuals with active TB 438 (blue dots), latent TB (orange dots) and healthy controls (grey dots). B) Clinical characteristics (rows) o 438 (blue dots), latent TB (orange dots) and healthy controls (grey dots). B) Clinical characteristics (rows) of all 439 active TB donors (columns) stratified by the negative value of PC1 (the more to the left indicating a 439 active TB donors (columns) stratified by the negative value of PC1 (the more to the left indicating a stronger 440 signature). TB manifestation: Pulmonary: (including 3 with pleuritis); 2 disseminated 440 signature). TB manifestation: Pulmonary: (including 3 with pleuritis); 2 disseminated 441 (pulmonary/abdominal/lymphnode and liver/lymphnode) and 2 extrapulmonary (lymphnode and soft tissue/osteitis). CRP = C-reactive protein. ESR = ervthrocyte sedimentation rate. Hb = hemoglobin. Alb = 442 tissue/osteitis), CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, Hb = hemoglobin, Alb = 443 albumin. Smear positive: sputum smear microscopy positive (5 of 14 with sputum): Cough: as reported by 443 albumin. Smear.positive; sputum smear microscopy positive (5 of 14 with sputum); Cough: as reported by patient: Presence of systemic symptoms (fever, weight loss, night sweats): No.S.Sympt = number of systemic 444 patient; Presence of systemic symptoms (fever, weight loss, night sweats); No.S.Sympt = number of systemic symptoms; night sweats, fever, and weight loss. symptoms; night sweats, fever, and weight loss.

446

#### 447 **Discussion**

448 The purpose of this study was to identify a protein signature in plasma that was enriched in 449 individuals with active TB compared to those with latent infection and healthy controls. We 450 used the Olink PEA method to simultaneously measure 92 proteins in plasma. Using co-451 expression analysis, we could identify 16 proteins that were co-expressed and highly 452 correlated with active TB. To test the validity of these findings, we used publicly available 453 transcriptomic datasets. First, we removed two proteins with very low differential expression 454 between active TB and controls. We then refined the signature by excluding two additional 455 proteins that were highly expressed in other lower respiratory tract infections. This allowed 456 us to generate a 12-protein signature that was highly specific when applied to independent TB 457 datasets. When retesting the signature on our own data it also retained a similar 458 discriminatory capacity as the initial 16-protein signature.

459

460 Albeit small, the study cohort is well defined, with microbiological verification of all active 461 TB cases, a wide range of disease severity and with large variation in patient origin, 462 reflecting the TB population in Sweden and thus increasing the likelihood of generalizability 463 to other geographic regions. Further, results were validated in nine transcriptomic data sets 464 including over 3000 individuals from four continents.

465 On an individual patient level, the signature was associated with disease activity with 466 a stronger protein signature significantly related to perturbations in common clinical 467 inflammatory markers (ESR and albumin) and reported symptoms.

469 We have shown that the identified signature is differentially expressed in independent TB 470 transcriptomic datasets and importantly, it is not expressed in patients with other lower 471 respiratory tract infections, which is essential if the signature is to be used as a diagnostic 472 screening test in a clinical setting as intended. However, when testing the signature in a sarcoidosis dataset (27), we observed a significant enrichment of the proteins. Sarcoidosis sarcoidosis dataset (27), we observed a significant enrichment of the proteins. Sarcoidosis 474 and TB have previously been shown to have similar gene expression patterns (27). Both 475 diseases demonstrate an interferon-driven gene up-regulation, although as shown by Blankley 476 et al, on a group level this pattern is more strongly expressed in active TB, reflecting disease 477 activity (27). We were not able to directly compare sarcoidosis versus active TB to assess if 478 the signal is higher in one group or the other. However, if the signature was to be used as a 479 screening test this potential overlap will likely not pose a significant diagnostic problem in a 480 clinical setting as symptoms and other clinical information such as radiology will help 481 separate the two conditions. Further, in TB high-endemic countries where a screening test is 482 most urgently needed, the prevalence of sarcoidosis is very low compared to pulmonary TB 483 (41, 42).

484

485 Lack of overlap between protein signatures for active TB has been previously described, and 486 the methods used to quantify proteins in different studies also vary (14). When comparing the 487 12-marker signature to recently published protein signatures (29-33, 40, 43-51) some 488 biomarkers reappear, although the overlap is limited. Additionally, in the published 489 proteomic studies there were none with processed data that included all the proteins of our 490 signature in their dataset, making us unable to use them to validate the signature proposed in 491 this study.

492 VEGF and IL-6, present in the 12-protein signature, together with IL-8 and IL-18, 493 constitute a 4-protein signature identified by Ahmad et al. (29). They analyzed 47 proteins with Luminex and the 4 selected proteins were validated in serum from three different patient 495 cohorts collected through the FIND initiative. The sensitivity for active TB in TB suspects 496 was 80% (95% CI, 73 to 85%), and the specificity was 65% (95% CI, 57-71%). Interestingly, 497 there was quite a large overlap between the Olink inflammation panel we used and their 47- 498 protein Luminex panel. Although IL-8 and IL-18 were more abundant in active TB patients 499 compared with healthy controls in our dataset (Figure S5), the fold-change values were low 500 compared with the proteins included in the 12-protein signature and were not significantly 501 higher when compared with latent TB individuals.

502 VEGF was also included in a 4-protein signature (CCL1, CXCL10, ADA-2, VEGF) 503 proposed by Delemarre et al. (30), where they compared active TB to treated and untreated 504 latent TB. The signature was validated in two separate patient cohorts with a sensitivity of 505 95% and a specificity of 90%. CXCL10 was also highly expressed in our analysis but was 506 removed due to its high expression in other lower respiratory tract infections. CCL1 and 507 ADA-2 were not analyzed in the current study.

508 Although VEGF was not included in the Chegou et al. (31) 7-protein signature, it was 509 increased in active TB patients in their cohort. Of their 7 proteins, IFN-gamma overlaps with 510 our 12-protein signature. CXCL10 (IP-10) again appears in their signature while the other 511 proteins (CRP, TTR, CFH, APO-A1, SSA) were not part of the proteins evaluated in our 512 study.

513 In 2021, Morris et al. (32) and Mutavhatsindi et al. (51) investigated the same 22 proteins as 514 Chegou et al. (31) and attempted to validate the 7-protein signature in patients with suspected 515 TB. In the first study, the sensitivity was very high (98%) while the specificity was low 516 (12%). They argued that this might be due to the different patient cohorts – primary care level 517 versus hospital care level. Instead, they identified a 9-protein signature (fibrinogen, alpha-2- 518 macroglobulin, CRP, MMP-9, transthyretin, complement factor H [CFH], IFN-gamma, IP-

519 10, and TNF-alpha) where IFN-gamma and IP-10 reappear. In the test set, the sensitivity was 520 92% (95% CI, 80-98%) and specificity 71% (95% CI, 56-84%) for diagnosing culture 521 verified TB from other diseases in TB suspects. Their second study (51) failed to validate the 522 7 marker signature. Instead, they proposed CRP and CCL1 as a signature that performed<br>523 equally well in both HIV- and HIV+ individuals. Trying to design a protein signature based 523 equally well in both HIV– and HIV+ individuals. Trying to design a protein signature based 524 on previous findings, Pedersen et al. (33) evaluated 9 proteins in pulmonary TB patients 525 compared to healthy controls. They found that IL-6, VEGFA, (and IP-10) are significantly 526 increased in active TB. Their proposed signature consists of IP-10 and 4 miRNA molecules, 527 including miR-29a, miR-146a, miR-99b and miR-221. IP-10 is also part of the 5-protein 528 signature identified by Luo et al. (52).

529 Garay-Baquero et al., analyzed more than 5000 peptides using Mass spectrometry on 530 a relatively small discovery cohort (10 individuals with active TB and 10 healthy controls) 531 (44). They identified 46 proteins to be overexpressed in active TB and selected 9 and 7 532 proteins for validation in larger populations in South Africa and the UK, respectively. They 533 used Luminex or ELISA and compared active TB to other respiratory diseases (ORD) and 534 healthy controls. The proposed 5 protein signature; CFHR5, LRG1, CRP, LBP, and SAA1, 535 performed well with an AUC > 0.8 in both settings for active TB vs ORD. There was no 536 overlap with the 12-protein signature identified here, and none of the proteins were among 537 the 136 proteins identified as associated with active TB (46 more abundant and 90 less 538 abundant) in their discovery phase, although the use of different methods makes direct 539 comparison difficult.

540 Another large proteomic study by de Groote et al., (53) used SOMAscan to measure 541 over 4000 proteins in 1470 patient samples from pulmonary TB patients and other TB suspect 542 cases and resulted in a 6-protein signature. Although their signature did not overlap with our 543 12-protein signature, IL-6 and MMP-1 were overexpressed in their active TB cases.

544 In summary, IFN-gamma, IL-6, and VEGF, together with IP-10 were identified as 545 markers for active TB in several previous studies, as well as identified in our study. These are 546 all regulated by STAT-1, which has previously been identified as an important immune 547 response pathway in Mtb infection (38), and potentially explains why these proteins are 548 identified in different studies. However, as found here, IP-10 is also highly expressed in other 549 severe infectious diseases and as such is likely not specific for TB in the absence of Mtb-550 specific stimulation (54).

551

552 To conclude, we identified a plasma biomarker signature associated with active TB 553 progression that was further corroborated in several independent datasets. Although the 554 signature can likely be optimized further by testing it in independent protein datasets, the 555 included biomarkers warrant further investigation and development for diagnostic purposes, 556 which will be critical to stopping the TB pandemic.

#### 557 558 **Acknowledgements**

559 We would foremost like to thank the study participants for agreeing to be included in the 560 study and donate study material. We would also like to thank the study nurses Monica 561 Modin, Jan Bellbrant, Anna Dahlberg and Lena Jansson for patient inclusion, Julius 562 Lautenbach and Victor Yman for constructive discussions about the analysis, and the 563 SciLifeLab Translational Plasma Profiling facility for their support and generating data for 564 this study. This study was supported by grants from the Swedish Research Council (2021- 565 03706), Magnus Bergvall Foundation (2019-03436), Åke Wiberg Foundation (M19-0559) 566 and the Swedish Medical Association (SLS-934363) to CS and grants from Swedish 567 Research Council (2019-04663 and 2020-03602) and the Heart- and Lung Foundation 568 (20180386 and 20200194) to GK.

569 570 **REFERENCES** 

571 1. Pai M, Nicol MP, Boehme CC. Tuberculosis Diagnostics: State of the Art and Future 572 Directions. Microbiol Spectr. 2016;4(5).

573 2. Dorman S. Advances in the diagnosis of tuberculosis: current status and future 574 prospects. The international journal of tuberculosis and lung disease : the official journal of 575 the International Union against Tuberculosis and Lung Disease. 2015;19(5):504-16.

576 3. Cohen A, Mathiasen VD, Schon T, Wejse C. The global prevalence of latent 577 tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3).

578 4. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. 579 Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic 580 review. Lancet Infect Dis. 2006;6(9):570-81.

581 5. Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert 582 MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in 583 adults. Cochrane Database Syst Rev. 2019;6:CD009593.

584 6. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. 585 Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in 586 adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 587 2021;2:CD009593.

588 7. Getnet F, Demissie M, Assefa N, Mengistie B, Worku A. Delay in diagnosis of 589 pulmonary tuberculosis in low-and middle-income settings: systematic review and meta-590 analysis. BMC Pulm Med. 2017;17(1):202.

591 8. WHO. Global Tuberculosis

592 Report.https://www.who.int/publications/i/item/9789240037021. 2021.

593 9. WHO. Consensus meeting report: development of a target product profile ( TPP) and a 594 framework for evaluation for a test for predicting progression from tuberculosis infection to 595 active disease. World Health Organization. License: CC BY-NC-SA 3.0 IGO. 2017.

596 10. Haas CT, Roe JK, Pollara G, Mehta M, Noursadeghi M. Diagnostic 'omics' for active 597 tuberculosis. BMC Med. 2016;14:37.

598 11. Weiner J, Kaufmann SH. High-throughput and computational approaches for 599 diagnostic and prognostic host tuberculosis biomarkers. Int J Infect Dis. 2017;56:258-62.

600 12. Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis 601 of pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med. 2016;4(3):213-24.

602 13. Blankley S, Graham CM, Levin J, Turner J, Berry MP, Bloom CI, et al. A 380-gene 603 meta-signature of active tuberculosis compared with healthy controls. Eur Respir J. 604 2016;47(6):1873-6.

605 14. MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM. 606 A systematic review of biomarkers to detect active tuberculosis. Nat Microbiol. 607 2019;4(5):748-58.

608 15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers 609 differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids 610 Res. 2015;43(7):e47.

611 16. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for 612 microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

613 17. Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity toward 614 precise disease classification. PLoS Comput Biol. 2008;4(11):e1000217.

615 18. Jonsson J, Westman A, Bruchfeld J, Sturegard E, Gaines H, Schon T. A borderline 616 range for Quantiferon Gold In-Tube results. PloS one. 2017;12(11):e0187313.

617 19. Wikell A, Jonsson J, Dyrdak R, Henningsson AJ, Eringfalt A, Kjerstadius T, et al. 618 The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis

619 Screening under Routine Conditions in a Low-Endemicity Setting. Journal of clinical 620 microbiology. 2021;59(12):e0137021.

621 20. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a 622 software environment for integrated models of biomolecular interaction networks. Genome

623 Res. 2003;13(11):2498-504.

624 21. Wang XJ, W.E.

625 Patil, P. . curatedTBData: Curation of existing 49 tuberculosis transcriptomic studies. R 626 package version 1.0.0. https://github.com/compbiomed/curatedTBData. 2021.

627 22. Herberg JA, Kaforou M, Gormley S, Sumner ER, Patel S, Jones KD, et al. 628 Transcriptomic profiling in childhood H1N1/09 influenza reveals reduced expression of 629 protein synthesis genes. The Journal of infectious diseases. 2013;208(10):1664-8.

630 23. Parnell GP, McLean AS, Booth DR, Armstrong NJ, Nalos M, Huang SJ, et al. A 631 distinct influenza infection signature in the blood transcriptome of patients with severe 632 community-acquired pneumonia. Crit Care. 2012;16(4):R157.

633 24. Suarez NM, Bunsow E, Falsey AR, Walsh EE, Mejias A, Ramilo O. Superiority of 634 transcriptional profiling over procalcitonin for distinguishing bacterial from viral lower 635 respiratory tract infections in hospitalized adults. The Journal of infectious diseases. 636 2015;212(2):213-22.

637 25. Chakraborty RK, Burns B. Systemic Inflammatory Response Syndrome. StatPearls. 638 Treasure Island (FL)2022.

639 26. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, et al. 640 Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, 641 pneumonias and lung cancers. PloS one. 2013;8(8):e70630.

642 27. Blankley S, Graham CM, Turner J, Berry MP, Bloom CI, Xu Z, et al. The 643 Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-644 Pulmonary and Pulmonary Tuberculosis. PloS one. 2016;11(10):e0162220.

645 28. Johnson WE, Odom A, Cintron C, Muthaiah M, Knudsen S, Joseph N, et al. 646 Comparing tuberculosis gene signatures in malnourished individuals using the 647 TBSignatureProfiler. BMC Infect Dis. 2021;21(1):106.

648 29. Ahmad R, Xie L, Pyle M, Suarez MF, Broger T, Steinberg D, et al. A rapid triage test 649 for active pulmonary tuberculosis in adult patients with persistent cough. Sci Transl Med. 650 2019;11(515).

651 30. Delemarre EM, van Hoorn L, Bossink AWJ, Drylewicz J, Joosten SA, Ottenhoff 652 THM, et al. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine 653 Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. 654 Front Immunol. 2021;12:725447.

655 31. Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A, et al. 656 Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of 657 active TB disease in African primary healthcare clinic attendees with signs and symptoms 658 suggestive of TB. Thorax. 2016;71(9):785-94.

659 32. Morris TC, Hoggart CJ, Chegou NN, Kidd M, Oni T, Goliath R, et al. Evaluation of 660 Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa. Front Immunol. 661 2021;12:639174.

662 33. Pedersen JL, Barry SE, Bokil NJ, Ellis M, Yang Y, Guan G, et al. High sensitivity 663 and specificity of a 5-analyte protein and microRNA biosignature for identification of active 664 tuberculosis. Clin Transl Immunology. 2021;10(6):e1298.

665 34. Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, et al. Anti-vascular 666 endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and 667 improves small molecule delivery. Proc Natl Acad Sci U S A. 2015;112(6):1827-32.

668 35. Kumar NP, Moideen K, Nancy A, Viswanathan V, Shruthi BS, Sivakumar S, et al. 669 Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed 670 sputum culture conversion in pulmonary tuberculosis. Sci Rep. 2019;9(1):18217.

671 36. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: 672 can disease be predicted? Trends Mol Med. 2007;13(5):175-82.

673 37. Kahnert A, Hopken UE, Stein M, Bandermann S, Lipp M, Kaufmann SH. 674 Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. The 675 Journal of infectious diseases. 2007;195(1):46-54.

- 676 38. Yi XH, Zhang B, Fu YR, Yi ZJ. STAT1 and its related molecules as potential 677 biomarkers in Mycobacterium tuberculosis infection. J Cell Mol Med. 2020;24(5):2866-78.
- 678 39. Mousavian Z, Khodabandeh M, Sharifi-Zarchi A, Nadafian A, Mahmoudi A. 679 StrongestPath: a Cytoscape application for protein-protein interaction analysis. BMC 680 Bioinformatics. 2021;22(1):352.

681 40. Schulman H, Niward K, Abate E, Idh J, Axenram P, Bornefall A, et al. Sedimentation 682 rate and suPAR in relation to disease activity and mortality in patients with tuberculosis. The 683 international journal of tuberculosis and lung disease : the official journal of the International 684 Union against Tuberculosis and Lung Disease. 2019;23(11):1155-61.

- 685 41. Collaborators GBDCRD. Prevalence and attributable health burden of chronic 686 respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease 687 Study 2017. Lancet Respir Med. 2020;8(6):585-96.
- 688 42. Labaki WW, Han MK. Chronic respiratory diseases: a global view. Lancet Respir 689 Med. 2020;8(6):531-3.
- 690 43. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, 691 Loosemore A, et al. Identification of diagnostic markers for tuberculosis by proteomic 692 fingerprinting of serum. Lancet. 2006;368(9540):1012-21.
- 693 44. Garay-Baquero DJ, White CH, Walker NF, Tebruegge M, Schiff HF, Ugarte-Gil C, et 694 al. Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis. JCI 695 Insight. 2020;5(18).
- 696 45. De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, et al. Highly 697 Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of 698 Latent Tuberculosis Infection. Journal of clinical microbiology. 2017;55(2):391-402.
- 699 46. Jiang TT, Shi LY, Chen J, Wei LL, Li M, Hu YT, et al. Screening and identification 700 of potential protein biomarkers for evaluating the efficacy of intensive therapy in pulmonary 701 tuberculosis. Biochem Biophys Res Commun. 2018;503(4):2263-70.
- 702 47. Liu Q, Pan L, Han F, Luo B, Jia H, Xing A, et al. Proteomic profiling for plasma 703 biomarkers of tuberculosis progression. Mol Med Rep. 2018;18(2):1551-9.
- 704 48. Mateos J, Estevez O, Gonzalez-Fernandez A, Anibarro L, Pallares A, Reljic R, et al. 705 Serum proteomics of active tuberculosis patients and contacts reveals unique processes 706 activated during Mycobacterium tuberculosis infection. Sci Rep. 2020;10(1):3844.
- 707 49. Sun H, Pan L, Jia H, Zhang Z, Gao M, Huang M, et al. Label-Free Quantitative 708 Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis 709 and Latent Infection. Front Microbiol. 2018;9:1267.
- 710 50. Xu D, Li Y, Li X, Wei LL, Pan Z, Jiang TT, et al. Serum protein S100A9, SOD3, and 711 MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-712 dimensional LC-MS/MS. Proteomics. 2015;15(1):58-67.
- 713 51. Mutavhatsindi H, van der Spuy GD, Malherbe ST, Sutherland JS, Geluk A, Mayanja-714 Kizza H, et al. Validation and Optimization of Host Immunological Bio-Signatures for a 715 Point-of-Care Test for TB Disease. Front Immunol. 2021;12:607827.
- 716 52. Luo J, Zhang M, Yan B, Li F, Guan S, Chang K, et al. Diagnostic performance of 717 plasma cytokine biosignature combination and MCP-1 as individual biomarkers for

718 differentiating stages Mycobacterium tuberculosis infection. The Journal of infection. 719 2019;78(4):281-91.

720 53. De Groote MA, Sterling DG, Hraha T, Russell TM, Green LS, Wall K, et al. 721 Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis. Journal of clinical microbiology. 2017;55(10):3057-71.

722 Active Pulmonary Tuberculosis. Journal of clinical microbiology. 2017;55(10):3057-71.<br>723 54. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, et a

54. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, et al. A 724 multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of

725 infection with M. tuberculosis. Tuberculosis (Edinb). 2011;91(3):260-7.